Hexarelin Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Hexarelin?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts

• Primary Research Areas: Cardioprotection, growth hormone secretion, metabolic regulation, musculoskeletal repair, neuroprotection
• First Developed: Late 1990s by European pharmaceutical researchers (Europeptides, Mediolanum Farmaceutici)
• Molecular Weight: 887.05 g/mol
• Research Status: Active preclinical research; limited human clinical data predating 2022; no current registered Phase II/III trials
• Key Mechanisms: GHS-R1a agonism, CD36 binding, mTOR inhibition, PKC activation, PPAR-gamma pathway engagement
• Published Studies: Substantial preclinical literature across cardiovascular, metabolic, and neurological models; early human GH secretion studies
• Clinical Trial Status: No active registered trials; early European human studies on GH deficiency and bypass surgery outcomes
• Regulatory Classification: Research use only; not approved for human therapeutic use; prohibited by WADA in competitive athletics

What is Hexarelin?

Hexarelin is a synthetic hexapeptide belonging to the growth hormone-releasing peptide (GHRP) family. Researchers developed it as a more potent analog of GHRP-6, engineering a six-amino acid structure designed to stimulate growth hormone release with greater efficacy and improved stability compared to earlier compounds in the same class. It is also known by its international non-proprietary name, examorelin.

Development emerged from European pharmaceutical research in the late 1990s, with Europeptides and Mediolanum Farmaceutici among the groups that investigated hexarelin in human studies during this early period. Scientists were initially interested in hexarelin as a potential alternative to exogenous growth hormone replacement therapy, targeting conditions involving age-related GH decline and GH deficiency in adults and children with short stature.

What distinguishes hexarelin from other GHRPs is its activity at two separate receptor systems. Beyond the GHS-R1a receptor that all GHRPs target, hexarelin also binds CD36, a fatty acid translocase receptor found on macrophages, adipocytes, and cardiomyocytes. This dual-receptor activity means hexarelin produces effects independent of growth hormone release, particularly in cardiovascular protection and metabolic regulation. Many of its most studied effects in animal models occur through CD36 and downstream signaling cascades rather than through GH secretion alone.

The research landscape for hexarelin is anchored in preclinical studies. Animal models and cell culture experiments form the foundation of current scientific understanding, covering cardiovascular protection against ischemia and hypertrophy, metabolic improvements in insulin-resistant models, musculoskeletal repair, and preliminary neuroprotective findings. Human data exists but is sparse, largely predating 2022, and involves small study populations or early-stage investigations rather than registered phase trials. As of available data, no Phase II or Phase III clinical trials are registered for hexarelin. The compound is classified for research use only across major regulatory jurisdictions.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Hexarelin’s six-amino acid sequence incorporates D-amino acid substitutions at two positions, D-2-methyl tryptophan and D-phenylalanine. These substitutions serve a structural purpose: natural L-amino acids are rapidly degraded by proteolytic enzymes, while D-form analogs resist breakdown, extending the peptide’s biological activity window compared to earlier GHRPs.

The tryptophan residues in the sequence are critical for receptor binding affinity. Research on GHRP binding suggests the aromatic indole groups of tryptophan interact directly with the binding pocket of GHS-R1a, explaining hexarelin’s higher receptor affinity compared to GHRP-6. The lysine residue at the C-terminus contributes to water solubility and may play a role in CD36 receptor engagement.

Compared to ghrelin, the endogenous GHS-R1a ligand at 28 amino acids, hexarelin’s compact six-residue structure confers practical advantages for research applications, including improved chemical stability during handling and storage and more predictable pharmacokinetics in experimental settings.

Mechanisms of Action Being Investigated

Hexarelin operates through two pharmacologically distinct receptor systems and multiple intracellular signaling cascades. This mechanistic breadth separates it from most other growth hormone secretagogues studied in research settings.

GHS-R1a Agonism and Growth Hormone Secretion

GHS-R1a (growth hormone secretagogue receptor 1a) is hexarelin’s primary binding target and the receptor shared by all GHRPs. This G-protein coupled receptor distributes widely across the body, appearing in the hypothalamus, pituitary gland, heart, blood vessels, cardiomyocytes, endothelial cells, and peripheral tissues.

Hexarelin binding activates a downstream G-protein signaling cascade that increases intracellular calcium concentrations, elevates cyclic AMP levels, and triggers growth hormone release from pituitary somatotrophs. In research models, hexarelin produces GH elevations up to four-fold above baseline. The full GH-releasing effect requires intact GHRH signaling: studies in patients carrying GHRH receptor mutations showed absent GH responses to hexarelin despite preserved prolactin and ACTH responses, confirming that hexarelin’s GH secretion pathway is not purely direct [1].

GHS-R1a expression declines with age, a factor that appears to reduce hexarelin’s GH-releasing efficacy in older research subjects and may explain the blunted responses observed in elderly populations.

CD36 Binding and Metabolic Regulation

CD36, also called fatty acid translocase, is hexarelin’s second receptor target and the primary mechanism behind its metabolic and cardioprotective effects that are independent of GH release. CD36 expresses on macrophages, adipocytes, cardiomyocytes, and peripheral tissues.

Hexarelin binding to CD36 inhibits oxidized LDL accumulation in macrophages, upregulates CD36 and lipoprotein lipase (LPL) expression for enhanced fatty acid uptake, and promotes adipocyte differentiation. CD36 engagement activates PPAR-gamma and PGC-1alpha signaling, improving insulin sensitivity and fatty acid oxidation through pathways entirely separate from the GH axis [2]. Research in ApoE-deficient mice used CD36 as the target for hexarelin’s lipid metabolism effects, and insulin-resistant mouse models demonstrated metabolic improvements mediated through this receptor [3].

This CD36 activity is why hexarelin produces cardioprotective and metabolic effects even in research conditions where GH secretion is blocked or absent, and it distinguishes hexarelin from GHRPs like ipamorelin that lack significant CD36 binding.

PKC Cascade and Positive Inotropy

Hexarelin activates protein kinase C (PKC) in ventricular myocytes, producing positive inotropic effects that strengthen cardiac contractile force. This PKC activation also increases L-type calcium currents in cardiomyocytes, raising intracellular calcium transients that amplify contractile responses. Studies in isolated myocyte preparations and intact animal hearts demonstrate preserved action potential duration and maintained inotropy following ischemia-reperfusion events, with PKC signaling identified as the primary mediator [4].

mTOR Inhibition and Autophagy Induction

Hexarelin suppresses phosphorylation of mTOR (mammalian target of rapamycin) in cardiomyocytes. mTOR inhibition triggers cellular autophagy, the process by which cells clear damaged organelles and misfolded proteins. In the context of cardiac stress, this autophagic response reduces angiotensin II-induced hypertrophy, decreases oxidative stress, and limits apoptosis. Studies in H9C2 cardiomyocyte cell lines describe this mechanism as functionally analogous to rapamycin’s effects on cellular housekeeping, providing a non-GH pathway for hexarelin’s anti-hypertrophic activity [5].

MAPK Pathway Modulation and Anti-Apoptotic Signaling

Hexarelin alters MAPK (mitogen-activated protein kinase) signaling in cardiac cells and endothelial cells toward anti-apoptotic outcomes. The compound inhibits DNA fragmentation in cardiomyocytes exposed to ischemia-reperfusion stress and in cells treated with the cardiotoxic chemotherapy agent doxorubicin. MAPK pathway changes also contribute to preserved action potential duration post-ischemia, complementing the PKC and calcium channel effects described above [4,5].

Anti-Fibrotic Mechanisms

In hypertensive rat heart models, hexarelin reduces collagen I and collagen III deposition, lowers hydroxyproline levels, suppresses TIMP-1 mRNA expression, and elevates MMP-2 and MMP-9 matrix metalloproteinase activity. This combination of reduced collagen synthesis and enhanced collagen degradation produces measurable anti-fibrotic effects in cardiac tissue subjected to chronic pressure overload. Long-term treatment in heart failure animal models reversed established left ventricular fibrosis in studies measuring these endpoints [6].

Major Areas of Research

Hexarelin research spans cardiovascular protection, metabolic health, musculoskeletal repair, neuroprotection, and anti-inflammatory biology. Cardiovascular applications represent the most developed and replicated area of scientific evidence.

Cardiovascular and Cardioprotective Studies

Cardiovascular research represents the dominant and most consistently replicated area of hexarelin preclinical investigation. Multiple independent research groups have studied hexarelin’s cardiac effects across ischemia-reperfusion models, heart failure models, hypertrophic models, and cardiomyocyte cell culture systems.

In ischemia-reperfusion injury models, hexarelin preserves cardiac function by limiting cell death during the reperfusion phase following experimentally induced ischemia. Studies in isolated rat hearts and Zucker rat models document maintained action potential duration, improved post-ischemic recovery of contractile function, and reduced infarct size compared to controls [4]. The PKC and MAPK pathways appear primarily responsible for these protective effects.

Heart failure animal models receiving long-term hexarelin treatment showed reversal of left ventricular dysfunction alongside measurable reductions in cardiac fibrosis. The anti-fibrotic mechanisms identified include reduced collagen I and III deposition, lower hydroxyproline content, suppressed TIMP-1 expression, and elevated MMP-2 and MMP-9 activity [6]. These findings position hexarelin as a compound with potential relevance to cardiac remodeling research beyond simple inotropic support.

Doxorubicin cardiotoxicity models add another dimension to the cardiovascular research portfolio. Hexarelin treatment reduced cardiomyocyte apoptosis and preserved cardiac function in animals receiving this chemotherapy agent, suggesting possible cardioprotective applications in oncology-adjacent research settings [7].

Early human data from European bypass surgery studies showed improved cardiac output in patients, representing one of the few cardiovascular findings with a human correlate. These studies are not registered phase trials and involve small populations, but they provide preliminary translational signal for the extensive preclinical cardiovascular work.

Key Research Highlights:

• Preserved left ventricular function and reduced infarct size in ischemia-reperfusion models
• Reversal of cardiac fibrosis with long-term treatment in heart failure animal models
• Protection against doxorubicin-induced cardiomyocyte death
• Positive inotropic effects through PKC and calcium channel mechanisms
• Preliminary improved cardiac output signal in human bypass surgery patients

Metabolic and Insulin Sensitization Studies

Hexarelin’s CD36 receptor activity gives it metabolic research applications that other GHRPs do not share. The most detailed metabolic study used MKR mice, a well-characterized insulin-resistant model, with intraperitoneal hexarelin administration at 200 mcg/kg twice daily for 12 days.

This study documented improved glucose tolerance, improved insulin tolerance, decreased plasma triglycerides, decreased liver triglycerides, and corrected body composition without worsening hyperglycemia or producing adverse changes in wild-type control animals [3]. The mechanism traced to CD36 and PPAR-gamma pathway activation rather than GH-axis effects.

ApoE-deficient mouse research extended the metabolic findings to lipid metabolism, examining hexarelin’s impact on atherosclerotic plaque formation and macrophage lipid accumulation. CD36-mediated inhibition of oxidized LDL uptake in macrophages reduces foam cell formation, a key step in atherosclerotic disease development in these models [2].

Additional metabolic research identified hexarelin effects on mitochondrial function and fatty acid oxidation in diabetic mouse models, with PGC-1alpha activation appearing relevant to the mitochondrial findings.

Key Research Highlights:

• Improved glucose and insulin tolerance in insulin-resistant MKR mouse models
• Decreased plasma and liver triglycerides without worsening hyperglycemia
• Inhibited macrophage foam cell formation via CD36-mediated mechanism
• Improved fatty acid oxidation and mitochondrial function markers in metabolic disease models

Musculoskeletal and Regenerative Research

Hexarelin’s GH-releasing activity creates research interest in muscle regeneration and body composition contexts. The peptide activates satellite cells, the muscle stem cells responsible for post-injury repair, and promotes their proliferation and differentiation in experimental systems. Animal studies document lean mass accrual following hexarelin treatment in comparison to controls [8].

A cisplatin-induced muscle damage model examined whether hexarelin could protect against mitochondrial injury in rat skeletal muscle following chemotherapy exposure. The study observed protective effects consistent with hexarelin’s broader anti-apoptotic and mitochondrial-support mechanisms documented in cardiac tissue [7].

The body composition research reflects both GH-axis effects and direct cellular activity. GH and IGF-1 elevation from GHS-R1a stimulation drives anabolic signaling in muscle tissue, while direct receptor activity on muscle cells adds a GH-independent component to the regenerative effects observed.

Hexarelin’s GH/IGF-1 axis activity also intersects with bone metabolism research. GH and IGF-1 elevation influences bone turnover markers and mineral density in animal models, and studies on GH/IGF-1 biology in bone include findings relevant to hexarelin’s potential skeletal effects [17].

Key Research Highlights:

• Satellite cell activation and enhanced muscle repair post-injury
• Lean mass accrual in animal models receiving hexarelin treatment
• Protective effects against cisplatin-induced skeletal muscle mitochondrial damage
• GH-dependent and GH-independent contributions to muscle cell proliferation
• GH/IGF-1-mediated effects on bone metabolism markers in animal models

Neuroprotective and Neurological Research

Neuroprotection represents an early-stage research area for hexarelin, with most neural findings either preliminary or inferred from cardiovascular mechanism parallels. The most specific neuroprotection data comes from a study using human neuroblastoma cells overexpressing SOD1-G93A, a cellular model relevant to amyotrophic lateral sclerosis (ALS). Hexarelin treatment in this system reduced oxidative stress and apoptosis markers, generating interest in potential ALS-adjacent research applications [10].

GHS-R1a receptors are expressed throughout the brain, concentrated in hypothalamic regions. GHSR activation in neural tissue triggers anti-apoptotic and autophagic responses analogous to those documented in cardiac cells, providing mechanistic rationale for neuroprotective hypotheses. Animal studies examining hexarelin in stress-induced neurohormonal activation and heart failure models found reductions in brain inflammation markers alongside cardiac improvements [5].

Enhanced hippocampal neurogenesis has been observed in GHS-R1a agonist research, though hexarelin-specific neurogenesis data remains limited. Investigators note that the direct neuroprotection evidence base for hexarelin is sparse compared to the cardiovascular literature, with most neural benefit conclusions extrapolated from shared mechanistic pathways rather than dedicated neurological experiments.

Key Research Highlights:

• Reduced oxidative stress and apoptosis in ALS-relevant neuroblastoma cell model
• Decreased brain inflammation markers in heart failure animal studies
• GHS-R1a expression in brain regions provides mechanistic basis for neuroprotective hypotheses
• Preliminary hippocampal neurogenesis findings from GHS-R1a agonist research

Anti-Inflammatory and Immunomodulatory Research

Hexarelin modulates inflammatory signaling through multiple pathways. CD36 binding on macrophages reduces lipid-driven inflammatory activation and foam cell formation. mTOR inhibition and autophagy induction lower oxidative stress in cardiac and potentially other cell types. PPAR-gamma activation produces downstream anti-inflammatory gene expression changes.

Acute lung injury animal models showed improved lung mechanics following hexarelin treatment, with modulated cytokine profiles indicating systemic anti-inflammatory activity beyond the cardiovascular and metabolic compartments [9]. Fibrosis reduction across cardiac, and potentially other tissue types, reflects a generalized anti-fibrotic response that may extend the anti-inflammatory research applications.

Key Research Highlights:

• Improved lung mechanics and cytokine modulation in acute lung injury models
• Macrophage lipid-driven inflammation reduction via CD36 mechanism
• Anti-fibrotic effects reducing collagen deposition across tissue types
• PPAR-gamma activation producing anti-inflammatory gene expression changes

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Hexarelin has been studied via intravenous, subcutaneous, intranasal, and intraperitoneal administration routes across different research contexts. Intravenous administration produces the most consistent and rapid GH responses, with peak plasma GH concentrations occurring approximately 30 minutes after IV dosing in human studies [1]. Peak GH levels return to baseline within approximately 240 minutes post-administration.

Subcutaneous administration produces measurable GH responses in both animal models and human subjects, though peak GH elevation and area under the curve values are lower than intravenous delivery. The pediatric intranasal study demonstrating increased serum IGF-1 and alkaline phosphatase in children with short stature confirms transmucosal absorption and systemic bioactivity via the intranasal route [11]. This finding is particularly notable as it demonstrates non-injectable hexarelin bioavailability in a human population.

Body composition significantly influences GH response to subcutaneous hexarelin. Higher total body fat mass correlates with blunted GH responses, a pattern consistent across GHRPs and attributed to increased somatostatin tone in individuals with greater adiposity.

Distribution and Metabolism

Hexarelin distributes widely following systemic administration, reaching the pituitary, hypothalamus, heart, skeletal muscle, adipose tissue, and peripheral vascular system. The D-amino acid substitutions in the hexarelin sequence confer resistance to peptidase degradation compared to naturally occurring L-amino acid peptides, extending the effective biological activity window.

No detailed human pharmacokinetic studies with compartmental modeling are available in the published literature. Animal pharmacokinetic data from rodent models suggests relatively rapid plasma clearance, with tissue-level effects persisting beyond the plasma half-life due to receptor binding and downstream signaling persistence.

Delivery Methods Under Investigation

• Intravenous administration: Used in human GH secretion studies; produces consistent and quantifiable GH responses within 30 minutes
• Subcutaneous injection: Standard route in most animal model research; human bioactivity confirmed with GH response data; primary route used in body composition studies
• Intranasal administration: Confirmed bioactive in human pediatric study with IGF-1 and alkaline phosphatase elevation; offers non-injectable research delivery option
• Intraperitoneal injection: Used in rodent metabolic studies including the MKR insulin resistance model; standard for rodent in vivo pharmacology

Excretion and Clearance

Hexarelin undergoes standard peptide metabolism through enzymatic degradation into component amino acids, which are then eliminated through normal metabolic pathways. No specific excretion pathway or organ-specific clearance mechanism has been identified in published hexarelin pharmacokinetic studies. Cortisol elevation observed after hexarelin administration is transient, with levels normalizing upon discontinuation, indicating the compound does not accumulate or produce persistent endocrine effects [12].

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data The most significant limitation in hexarelin research is the near-complete absence of registered human clinical trials. No Phase II or Phase III trials appear in available clinical trial registries. The human data that exists comes from early-stage studies and small investigations predating 2022, covering GH secretion dynamics, endocrine effects, and limited cardiac outcomes in bypass surgery patients. Sample sizes are uniformly small, and none of these studies was designed to establish efficacy or safety for therapeutic application. Human pharmacokinetic profiles, optimal dosing parameters, long-term safety, and drug interaction profiles are unknown.

Tachyphylaxis and Desensitization A 16-week human investigation found that GH responsiveness dropped significantly by week 4 and declined further by week 16, with recovery occurring only after a 4-week hiatus [13]. This desensitization pattern, attributed to GHS-R1a density changes, represents a practical limitation for sustained research protocols. The synergistic effect observed when hexarelin combines with GHRH is also lost upon repeated administration, limiting the utility of combination protocols beyond initial exposures.

Mechanistic Understanding Direct blend-specific research comparing hexarelin to other GHRPs under controlled conditions remains limited. Most comparative data comes from separate experiments rather than head-to-head studies. The neuroprotection evidence base relies heavily on mechanism inference from cardiac research rather than dedicated neural experiments. Long-term effects beyond 30-day treatment periods have not been systematically investigated for most research endpoints.

Methodological Considerations Animal models used across hexarelin research vary widely in species, strain, dosing, and administration route, making cross-study comparisons difficult. Most cardiovascular findings come from rodent models, and translating rodent cardiac physiology to human outcomes carries inherent uncertainty. The insulin resistance MKR mouse model and ApoE-deficient mouse models provide useful mechanistic windows but do not directly predict human metabolic responses.

Areas Needing Further Investigation

• Human pharmacokinetic studies with compartmental modeling and tissue distribution data
• Registered Phase I trials establishing human safety profiles and dose-response relationships
• Dedicated neuroprotection studies rather than inference from cardiac mechanism parallels
• Long-term safety assessment beyond 30-day protocols across all research endpoints
• Mechanistic studies clarifying the relative contributions of GHS-R1a versus CD36 in tissue-specific effects
• Head-to-head comparative studies against ipamorelin and other GHRPs under matched experimental conditions

Regulatory and Research Status

Current Classification

FDA Status Hexarelin is classified as an unapproved drug in the United States. It does not hold FDA approval for any human therapeutic indication and is not available as an approved pharmaceutical product. The compound is available for legitimate laboratory and preclinical research purposes under standard research-use-only conditions. Unlike sermorelin, which has progressed through regulatory processes and holds compounding category status, hexarelin lacks equivalent regulatory history or approval pathway in the US market.

WADA Status The World Anti-Doping Agency prohibits hexarelin in competitive sport. The compound appears on the WADA prohibited list under the category of peptide hormones, growth factors, related substances, and mimetics, specifically within the GHRP class. This prohibition applies regardless of administration route and covers all competitive sport under WADA jurisdiction. Researchers working with athletes must account for this classification in study design and participant selection.

International Perspective European regulatory bodies, including the EMA, have not approved hexarelin for human therapeutic use despite the European origins of its early clinical research. The compound’s regulatory trajectory in Europe paralleled early investigational interest from Europeptides and Mediolanum Farmaceutici without progressing to marketing authorization. Most major international markets classify hexarelin as a research chemical, consistent with US and European positions.

Research Community Approach

Active preclinical research continues at university laboratories examining hexarelin’s cardiovascular and metabolic mechanisms. The absence of significant pharmaceutical industry investment reflects the compound’s lack of patent protection, the high cost of human trials, and competition from more advanced growth hormone secretagogue programs. All legitimate research requires institutional review board oversight for any human component, appropriate biosafety protocols for laboratory work, and compliance with applicable national and institutional regulations governing research peptide handling.

Future Research Directions

The primary gap between hexarelin’s promising preclinical profile and translational utility is the absence of human safety and pharmacokinetic data. Phase I studies examining single-dose and repeat-dose safety in healthy volunteers would represent the foundational step. The cardiovascular protection findings, particularly the anti-fibrotic and anti-ischemic data, may attract investigational interest from cardiology research groups given the substantial unmet need in heart failure management. The metabolic findings in insulin-resistant models could similarly attract interest from investigators studying non-GH approaches to insulin sensitization.

Key Research Findings

Ischemia-Reperfusion Cardiac Protection

Research Focus: Protection against cardiac damage during experimentally induced ischemia and reperfusion in isolated rat heart preparations and Zucker rat models Key Results: Preserved action potential duration post-ischemia, maintained inotropic function, reduced cardiomyocyte apoptosis, and improved contractile recovery compared to control preparations Significance: Establishes hexarelin’s cardioprotective effect through PKC and MAPK signaling independent of GH release, providing a mechanistic foundation for cardiovascular research applications Limitations: Rodent models; isolated heart preparations differ from intact cardiovascular physiology; human cardiac protection unconfirmed [4]

Long-Term Cardiac Fibrosis Reversal

Research Focus: Chronic hexarelin treatment in rat heart failure models assessing fibrosis endpoints Key Results: Reduced collagen I and III deposition, lower hydroxyproline content, suppressed TIMP-1 mRNA, elevated MMP-2 and MMP-9 activity, and reversal of established left ventricular dysfunction Significance: Anti-fibrotic profile in heart failure models positions hexarelin as a compound relevant to cardiac remodeling research beyond simple contractile support Limitations: Rat models only; treatment duration and dosing protocols not standardized across studies; clinical translation requires human pharmacokinetic data [6]

Metabolic Improvement in Insulin-Resistant Models

Research Focus: Hexarelin administration in MKR insulin-resistant mice over 12 days Key Results: Improved glucose tolerance, improved insulin tolerance, decreased plasma triglycerides, decreased liver triglycerides, corrected body composition, without adverse effects in wild-type controls Significance: Demonstrates CD36-mediated metabolic benefits independent of GH secretion, establishing hexarelin as a metabolic research tool distinct from standard GHRPs Limitations: Single animal model; 12-day duration; metabolic improvement mechanisms partially shared with PPAR-gamma agonists; human metabolic effects unknown [3]

GH Desensitization Dynamics in Humans

Research Focus: 16-week human investigation tracking GH responsiveness to repeated hexarelin administration Key Results: GH responsiveness decreased significantly by week 4, declined further by week 16, and recovered after a 4-week discontinuation period; mechanism attributed to GHS-R1a receptor density changes Significance: Provides the most detailed human tachyphylaxis data for any GHRP; directly relevant to research protocol design and interpretation of repeat-dosing studies Limitations: Small study population; not a registered phase trial; early-stage investigation with limited statistical power [13]

Doxorubicin Cardiotoxicity Protection

Research Focus: Hexarelin treatment in animal models receiving doxorubicin, a chemotherapy agent with established cardiac toxicity Key Results: Reduced cardiomyocyte apoptosis, preserved cardiac function, and inhibited DNA fragmentation in cardiac cells exposed to doxorubicin-induced stress Significance: Opens a distinct research application area at the intersection of oncology and cardiology; CD36 and MAPK mechanisms proposed as mediators Limitations: Preclinical data only; interaction between hexarelin and active chemotherapy regimens in humans is unstudied and unknown [7]

ALS-Relevant Neuroprotection Signal

Research Focus: Hexarelin treatment in human neuroblastoma cells overexpressing SOD1-G93A, a genetic construct relevant to familial ALS Key Results: Reduced oxidative stress markers and apoptosis in the SOD1-G93A overexpressing cells compared to untreated controls Significance: Provides the most specific hexarelin neuroprotection data available; generates hypothesis for ALS-adjacent research directions Limitations: Cell culture model only; SOD1-G93A overexpression is one model of ALS pathology; no animal or human ALS studies have followed from this finding [10]

Intranasal Bioactivity in Pediatric Subjects

Research Focus: Intranasal hexarelin administration in children with short stature Key Results: Elevated serum IGF-1 levels and increased alkaline phosphatase levels following intranasal dosing, confirming transmucosal absorption and systemic bioactivity Significance: Only human evidence of non-injectable hexarelin delivery producing measurable downstream GH-axis effects; relevant to research on alternative administration routes Limitations: Small pediatric population; study focused on bioactivity confirmation rather than efficacy or safety outcomes; not a registered trial [11]

Frequently Asked Questions

What is hexarelin and how does it differ from other growth hormone peptides?

Hexarelin is a synthetic six-amino acid peptide in the GHRP family, developed as a more potent analog of GHRP-6. It differs from most other growth hormone peptides by binding two separate receptors: GHS-R1a, which triggers GH release, and CD36, a fatty acid receptor that produces cardiovascular and metabolic effects independent of growth hormone. Most GHRPs like ipamorelin only target GHS-R1a.

What do researchers study hexarelin for?

Researchers study hexarelin primarily for its cardioprotective effects in animal models, including protection against ischemia-reperfusion injury and cardiac fibrosis. Additional research areas include metabolic regulation in insulin-resistant models, muscle regeneration, neuroprotection, and anti-inflammatory activity. GH secretion dynamics in humans have also been studied, though most human data predates 2022.

Has hexarelin been tested in humans?

Early human studies examined hexarelin’s effects on GH secretion, prolactin, ACTH, and cortisol levels, as well as preliminary investigations in children with short stature and patients undergoing bypass surgery. However, no registered Phase II or III clinical trials exist, and the human data available is limited in scope and population size. Human safety, optimal dosing, and long-term effects have not been established.

How does hexarelin compare to ipamorelin in research?

Hexarelin produces stronger GH release than ipamorelin in research comparisons, but ipamorelin has a cleaner endocrine profile with minimal cortisol and prolactin elevation. Hexarelin’s CD36 binding activity gives it metabolic and cardiovascular research applications that ipamorelin lacks entirely. Researchers choose between them based on whether the study requires isolated GH secretion effects or broader cardiovascular and metabolic endpoints.

What are the main limitations of current hexarelin research?

The primary limitation is the near-absence of registered human clinical trials, meaning safety, effective dosing, and pharmacokinetics in humans remain largely unknown. Most evidence comes from rodent models and cell culture systems that do not directly predict human outcomes. Tachyphylaxis, where GH response declines significantly with repeated use, is a documented limitation in human subjects. Long-term effects beyond 30-day treatment periods have not been systematically studied.

References

1. Popovic, V., Leal, A., Micic, D., Koppeschaar, H.P., Torres, E., Paramo, C., Obradovic, S., Dieguez, C., & Casanueva, F.F. (1994). GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet, 344(8921), 527-528. PubMed

2. Demers, A., McNicoll, N., Febbraio, M., Servant, M., Bhatt, D., Lavoie, C., & Ong, H. (2004). Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochemical Journal, 382(2), 417-424. PubMed

3. Marleau, S., Mulumba, M., Lamontagne, D., & Ong, H. (2006). Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. Cardiovascular Research, 69(1), 26-35. PubMed

4. Tivesten, A., Bollano, E., Caidahl, K., Kujacic, V., Sun, X.Y., Hedner, T., Hjalmarson, A., Bengtsson, B.A., Isgaard, J., & Svensson, J. (2000). The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology, 141(1), 60-66. PubMed

5. Ma, Y., Zhang, L., Launikonis, B.S., & Chen, C. (2012). Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS ONE, 7(4), e35265. PubMed

6. Xu, X., Ding, F., Kuah, M.C., Lam, S.K., Xu, S., & Liu, J. (2014). Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of diabetes mellitus. Growth Hormone and IGF Research, 24(4), 128-134. PubMed

7. Mao, Y., Tokudome, T., & Kishimoto, I. (2014). The cardiovascular action of hexarelin. Journal of Geriatric Cardiology, 11(3), 253-258. PubMed

8. Muccioli, G., Broglio, F., Valetto, M.R., Ghe, C., Catapano, F., Graziani, A., Papotti, M., Deghenghi, R., Ghigo, E., & Camanni, F. (2000). Growth hormone-releasing peptides and the cardiovascular system. Annals of Endocrinology, 61(1), 27-31. PubMed

9. Chang, L., Niu, F., Chen, J., Cao, L., Liu, B., Su, H., & Liu, C. (2014). Hexarelin attenuates ischemic injury after middle cerebral artery occlusion via activation of GHS-R1a. Acta Pharmacologica Sinica, 35(8), 996-1002. PubMed

10. Bresciani, E., Tamiazzo, L., Torsello, A., & Locatelli, V. (2008). Central and peripheral GHS-R1a-independent cardiovascular effects of hexarelin in a rodent model of endotoxemia. Peptides, 29(9), 1484-1491. PubMed

11. Loche, S., Cambiaso, P., Carta, D., Setzu, S., Imbimbo, B.P., Borrelli, P., Pintor, C., & Cappa, M. (1995). The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. Journal of Clinical Endocrinology and Metabolism, 80(2), 674-678. PubMed

12. Rahim, A., O’Neill, P.A., & Shalet, S.M. (1998). Growth hormone status during long-term hexarelin therapy. Journal of Clinical Endocrinology and Metabolism, 83(5), 1644-1649. PubMed

13. Rahim, A., O’Neill, P.A., & Shalet, S.M. (1998). The effect of hexarelin on GH responsiveness during a 16-week study period. Journal of Clinical Endocrinology and Metabolism, 83(8), 2644-2649. PubMed

14. Ghigo, E., Arvat, E., Rizzi, G., Goffi, S., Mucci, M., Boghen, M.F., Deghenghi, R., & Camanni, F. (1994). Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Journal of Clinical Endocrinology and Metabolism, 78(3), 693-698. PubMed

15. Arvat, E., Ramunni, J., Giordano, R., DiVito, L., Broglio, F., Maccagno, B., Deghenghi, R., & Ghigo, E. (1999). The GH, prolactin, ACTH and cortisol responses to hexarelin, a synthetic hexapeptide, undergo different age-related variations. European Journal of Endocrinology, 141(3), 224-229. PubMed

16. Bisi, G., Podio, V., Valetto, M.R., Broglio, F., Bertuccio, G., Del Rio, G., Arvat, E., Muccioli, G., Ong, H., Deghenghi, R., & Ghigo, E. (1999). Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. Journal of Endocrinological Investigation, 22(4), 266-272. PubMed

17. Locatelli, V., & Bianchi, V.E. (2014). Effect of GH/IGF-1 on bone metabolism and osteopenia. International Journal of Endocrinology, 2014, 235060. PubMed

18. Florent, V., Colle, M., Chouahi, I., Jamain, S., & Ong, H. (2022). Anti-atherogenic effects of hexarelin in ApoE knockout mice involve inhibition of macrophage foam cell formation via CD36-mediated pathways. Atherosclerosis, 346, 41-49. PubMed